PAP
OCUL icon

Persistent Asset Partners’s Ocular Therapeutix OCUL Stock Holding History

Persistent Asset Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,984
Closed -$291K – 435
2025
Q4 		$291K Buy
+23,984
New +$291K 0.13% 186

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Persistent Asset Partners's OCUL Position: Q1 2026 in Review

Persistent Asset Partners sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 23,984 shares — an estimated $291K sold.

Persistent Asset Partners first reported a position in OCUL in Q4 2025 and held it in 1 quarter. The position peaked at $291K in Q4 2025. 270 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Persistent Asset Partners reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 23,984 Ocular Therapeutix shares in Q1 2026, an estimated $291K.
  • Persistent Asset Partners first reported a position in Ocular Therapeutix in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Ocular Therapeutix position peaked at $291K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.